Opinions+ By Abhinav Shashank and Smriti Khera Biopharma companies need digital portfolios to succeed in a disease management future
Opinions+ By Birgit Girshick Biopharma’s response to the next pandemic depends on collaboration and the ability to learn and fail fast
Opinions+ By Jose-Carlos GutiƩrrez-Ramos Manufacturing at the edge: smaller, localized, and agile factories will be key to biopharma drug production
Opinions+ By James Biggins Med tech companies that approach value-based care contracting wisely can earn first-mover advantage
Opinions+ By Jim King and Philip Burton What’s blocking health care boards’ progress in diversity, equity, and inclusion?
Opinions+ By Prasad Dindigal Forget the hype and embrace the reality: How AI can improve health outcomes right now
Opinions+ By Marc Herant and Jason Brauner Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D
Opinions+ By Nicole Paraggio, Nicole van Poppel and Selen Karaca-Griffin Reimagining R&D can cut drug development costs from billions to millions
Opinions+ By Elizabeth Ruzzo 8 reasons ‘move fast and break things’ doesn’t work for health care companies
Opinions+ By Andy Plump Maintaining trust in science is crucial to public health. Here’s how the biopharma industry can help
Opinions+ By Andrei Iancu and David Kappos Why does the FDA want to stop improving medicines via patent ‘areas of concern’?
Opinions+ By Dawn Anderson Digital clinical trials can personalize patient engagement, accelerate therapy development
Opinions+ By Monique K. Mansoura A 10-point plan for sustaining the biopharma industrial base for a more secure nation
Opinions+ By Chris Plance and Nilesh Chandra Bringing clarity and consistency to CMS’s hospital price transparency rule will be a win for all
Opinions+ By Bret Schiller Viruses, variants, and the business of health care: Preparing for another wave now and the years ahead
Opinions+ By Daphne Zohar Stifling biopharma mergers would kill the innovation economy that generates new therapies
Opinions+ By Stephen Ferguson SARS-CoV-2 brought the world to its knees. Its digital twin is helping bring us back
Opinions+ By John Freedman The many benefits of expanding the reach of state all-payer claims databases
Opinions+ By Raymond Deshaies ‘Induced proximity’ is why I am optimistic about treating undruggable diseases
Opinions+ By Hensley Evans and Sharon Suchotliff The pharma industry needs to measure patient experience from the patients’ perspectives
Opinions+ By Tonya Winders Faster approval of complex generics is central to affordable, equitable care
Opinions+ By Shira Machluf How the FDA’s ‘master plan’ will affect NIH funding for digital medicine projects
Opinions+ By Fiona Gilbert, Mona Flores and Ittai Dayan Improving health care means improving data diversity. Federated learning can help
Opinions+ By Giacomo Chiesi More pharma companies should make the move toward becoming environmentally sustainable